Vosoritide
Also called Voxzogo, BMN-111
Subcutaneous (under the skin)Product label
Research reference
Product label
Voxzogo weight-band daily kit
Once daily; exact amount and vial strength selected from the current body-weight table
Regular growth, weight and safety review while growth plates remain open
Voxzogo product label ↗When results may show
- When change was measured
- Growth is assessed longitudinally, not as an immediate effect. Hydration/food and blood-pressure precautions matter.
- When to assess
- Regular growth, weight and safety review while growth plates remain open
- Conditions and limitations
- Children with achondroplasia and open growth plates. Not an adult height or body-composition starter. Reconstitution uses the exact co-packaged kit instructions, not generic BAC-water arithmetic.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Sources: Voxzogo product label
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Vosoritide describe 150–600 mcg per administration. Descriptive only, not a recommendation.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.98× single dose
- Time to steady state
- 2hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Voxzogo product labelNot an adult height or body-composition starter. Reconstitution uses the exact co-packaged kit instructions, not generic BAC-water arithmetic.
Next steps
Vosoritide beginner guideOpen Vosoritide planning worksheetEstimate Vosoritide vial costTrack Vosoritide notes